ARCHIVES

DeVita’s “Radical” Statement – Resectability Rate Should Be The Cure Rate

This article is from The Cancer Letter archive.

Vol. 02 No. 40 | October 1, 1976

Download PDF Visit The Full Archive

Related Articles

In Brief: Robert Miller To Head International Affairs Office’ Pitot: No Basis for 20% Estimate

December 1, 1978

Navelbine+Herceptin: 78% Response In Breast Cancer

November 29, 2002

Decline In Breast Cancer May Be Related to Drop In HT

March 25, 2011

User Fees Proposed For FDA Oversight Services; Industry Groups Call It “Tax On Innovations”

January 20, 1989

FDA Publishes Parallel Track Rules, Accelerated Drug Approval Initiative

April 25, 1992

St. Jude, Washington University Plan $65 Million Pediatric Cancer Genome Project

January 29, 2010